

# OPTİK NÖROPATİLERE NÖROLOJİK YAKLAŞIM

# 19

**Şennur DELİBAŞ KATI<sup>1</sup>**

Optik nöropati çeşitli nedenlere bağlı olarak gelişen optik sinir inflamasyonudur. En sık görmede azalma veya bulanıklık görülür. Eşlik eden diğer nörolojik bulguların varlığı ileri tetkik gerektirir. Ayrıntılı oftalmolojik ve fundoskopik muayene için Göz Hastalıkları konsültasyonu yapılmalıdır. Fundus muayenesinde optik disk ödemli, sınırları silik olarak görülür. Optik sinir başı etrafında hemorajiler görülebilir. Bazen optik disk normal görünümde olabilir çünkü patoloji, optik diskin arkasındaki segmenti tutuyor olabilir.

Optik nöropatilerin sınıflandırması aşağıdaki gibidir.

- ▶ İskemik; Vasküler patolojiye bağlı (Arter,ven), vb.
- ▶ Demiyelizan; Multiple Skleroz(MS), Nöromyelitis Optika(NMO), vb.
- ▶ Kompresif; Optik sinire bası yapan kitleler
- ▶ Travmatik; Optik sinir travması
- ▶ Herediter (Leber'in herediter optik nöropatisi)
- ▶ Radyasyon ile ilişkili
- ▶ Toksik-Nutrisyonel; Nutrisyonel, ilaç(Etambutol, İzoniazid, vb.), sigara ve alkol
- ▶ Sistemik ve oküler hastalıklar: Sarkoidoz, Sifiliz, vb.

## **KLİNİK BULGULAR**

En sık monoküler görme kaybı şeklinde semptom verir. Ağrı olabilir. Bunun dışında afferent pupil defekti, santral skotom, renkli görmenin kaybı, papillit ve optik atrofi şeklinde klinik verebilir.

<sup>1</sup> Uzman Dr, Sağlık Bilimleri Üniversitesi Antalya Eğitim Araştırma Hastanesi Nöroloji Kliniği, sennurdelibas@yahoo.com

**KAYNAKLAR**

1. Biousse, Valérie MD Adams and Victor's Principles of Neurology, 9th Edition, Journal of Neuro-Ophthalmology: September 2007 - Volume 27 - Issue 3 - p 246 doi: 10.1097/WNO.0b013e31814a6067
2. Bradley's Neurology in Clinical Practice, Sixth Edition John C.M. Brust. Neurology Sep 2013, 81 (12) 1104-1105; DOI:10.1212/WNL.0b013e3182a4a566.
3. Nöroloji Temel Kitabı. 1. Baskı. Emre M. 2012. İstanbul.
4. Aminoff MJ. Review of *Merritt's Neurology*, 13th ed. *JAMA Neurol.* 2016. doi:10.1001/jama-neurol.2016.1005.
5. Yaşar E. 2020. Optik Nöropatiler. Yaşar E, Gürlevik U. Retina Acillerinde Tanıdan Tedaviye. 195-219. Akademisyen Yayınevi.
6. Sadun AA. The afferent visual system: Anatomy and Physiology. In: Ophthalmology, 2nd ed, Yanoff M, Duker JS (Eds), Mosby, St. Louis 2004. p.186.
7. Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. *Am J Ophthalmol* 2001; 132:743.
8. Buono LM, Foroosan R. Perioperative posterior ischemic optic neuropathy: review of the literature. *Surv Ophthalmol* 2005; 50:15.
9. Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. *J Neuroophthalmol* 1995; 15:9.
10. Liu GT. Visual loss: optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management, Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, Philadelphia 2001.
11. Gass A, Moseley IF. The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage. *J Neurol Sci* 2000; 172 Suppl 1:S17.
12. Dickersin K, Donald Everett D, Feldon S et al. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. *JAMA* 1995; 273:625.
13. Dickersin K, Manheimer E, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy. *Cochrane Database Syst Rev* 2006; :CD001538.
14. Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. *Am J Ophthalmol* 2002; 134:317.
15. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. *Am J Med* 2001; 111:211.
16. Lee AG, Brazis PW. Systemic infections of neuro-ophthalmic significance. *Ophthalmol Clin North Am* 2004; 17:397.
17. Chan CK, Limstrom SA, Tarasewicz DG, Lin SG. Ocular features of west nile virus infection in North America: a study of 14 eyes. *Ophthalmology* 2006; 113:1539.
18. Golnik KC. Infectious optic neuropathy. *Semin Ophthalmol* 2002; 17:11.
19. Fukushima A, Yasuoka M, Tsukahara M, Ueno H. A case of cat scratch disease neuroretinitis confirmed by polymerase chain reaction. *Jpn J Ophthalmol* 2003; 47:405.
20. Gildden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. *Nat Clin Pract Neurol* 2007; 3:82.
21. Küçükerdönmez C, Akova YA, Yılmaz G. Ocular toxoplasmosis presenting as neuroretinitis: report of two cases. *Ocul Immunol Inflamm* 2002; 10:229.
22. Smith GT, Goldmeier D, Migdal C. Neurosyphilis with optic neuritis: an update. *Postgrad Med J* 2006; 82:36.
23. Krim E, Guehl D, Burbaud P, Laguëny A. Retrobulbar optic neuritis: a complication of Lyme disease? *J Neurol Neurosurg Psychiatry* 2007; 78:1409.
24. Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. *Ophthalmology* 1990; 97:339.
25. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch Neurol* 2003; 60:504.

26. Evliyaoglu F, Karadag R, Burakgazi AZ. Ocular neuropathy in peripheral neuropathies. *Muscle Nerve* 2012; 46:681.
27. Ginestal RC, Plaza JF, Callejo JM, et al. Bilateral optic neuritis and Guillain-Barré syndrome following an acute *Mycoplasma pneumoniae* infection. *J Neurol* 2004; 251:767.
28. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. *QJM* 2009; 102:449.
29. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. *J Neurol* 2014; 261:17.
30. Theodoridou A, Settas L. Demyelination in rheumatic diseases. *J Neurol Neurosurg Psychiatry* 2006; 77:290.
31. Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. *Clin Rheumatol* 1999; 18:124.
32. Monteiro ML, Borges WI, do Val Ferreira Ramos C, et al. Bilateral optic neuritis in Wegener granulomatosis. *J Neuroophthalmol* 2005; 25:25.
33. Kansu T, Kirkali P, Kansu E, Zileli T. Optic neuropathy in Behçet's disease. *J Clin Neuroophthalmol* 1989; 9:277.
34. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. *Gastroenterology* 2005; 129:819.
35. Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma. *Neurology* 1984; 34:788.
36. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. *Ann Neurol* 2001; 49:146.
37. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. *Ann Neurol* 2003; 54:38.
38. Lee AG, Tang RA, Roberts D, et al. Primary central nervous system lymphoma involving the optic chiasm in AIDS. *J Neuroophthalmol* 2001; 21:95.
39. Howell N. LHON and other optic nerve atrophies: the mitochondrial connection. *Dev Ophthalmol* 2003; 37:94.
40. Kermode AG, Moseley IF, Kendall BE, et al. Magnetic resonance imaging in Leber's optic neuropathy. *J Neurol Neurosurg Psychiatry* 1989; 52:671.
41. Lamirel C, Cassereau J, Cochereau I, et al. Papilloedema and MRI enhancement of the prechiasmatic optic nerve at the acute stage of Leber hereditary optic neuropathy. *J Neurol Neurosurg Psychiatry* 2010; 81:578.
42. Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. *Br J Ophthalmol* 2003; 87:48.
43. Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. *Ophthalmol Clin North Am* 2004; 17:481.
44. Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. *Mayo Clin Proc* 2003; 78:1409.
45. J. Malilay, D.T. Miller, A.L. Sowell et al. Cuba Neuropathy Field Investigation Team. Epidemic optic neuropathy in Cuba--clinical characterization and risk factors. *N Engl J Med* 1995; 333:1176.
46. Sadun AA. Metabolic optic neuropathies. *Semin Ophthalmol* 2002; 17:29.
47. Kisimbi J, Shalchi Z, Mahroo OA, et al. Macular spectral domain optical coherence tomography findings in Tanzanian endemic optic neuropathy. *Brain* 2013; 136:3418.
48. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. *Surv Ophthalmol* 1998; 42:535.
49. Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. *Radiother Oncol* 1994; 30:17.
50. Simsek T, Simsek E, Ilhan B, et al. Traumatic optic nerve avulsion. *J Pediatr Ophthalmol Strabismus* 2006; 43:367.
51. Levin LA, Beck RW, Joseph MP, et al. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. *Ophthalmology* 1999; 106:1268.

52. Steinsapir KD. Treatment of traumatic optic neuropathy with high-dose corticosteroid. *J Neuroophthalmol* 2006; 26:65.
53. Balcer LJ. Clinical practice. Optic neuritis. *N Engl J Med* 2006; 354:1273.
54. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. *Lancet Neurol* 2005; 4:111.
55. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. *Am J Ophthalmol* 2005; 139:1101.
56. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. *Neurology* 1995; 45:244.
57. Wakakura M, Minei-Higa R, Oono S, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). *Jpn J Ophthalmol* 1999; 43:127.
58. Roed H, Frederiksen J, Langkilde A, et al. Systemic T-cell activation in acute clinically isolated optic neuritis. *J Neuroimmunol* 2005; 162:165.
59. Söderström M, Link H, Xu Z, Fredriksson S. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. *Neurology* 1993; 43:1215.
60. Frederiksen JL, Madsen HO, Ryder LP, et al. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. *Arch Neurol* 1997; 54:76.
61. De la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. *Br J Ophthalmol* 2006; 90:551.
62. Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. *Eye (Lond)* 2001; 15:469.
63. Hwang JM, Lee YJ, Kim MK. Optic neuritis in Asian children. *J Pediatr Ophthalmol Strabismus* 2002; 39:26.
64. Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. *Neurology* 2006; 67:258.
65. Beck RW, Kupersmith MJ, Cleary PA, Katz B. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. *Ophthalmology* 1993; 100:691.
66. Beck RW. The Optic Neuritis Treatment Trial. *Arch Ophthalmol* 1988; 106:1051.
67. Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. *Am J Ophthalmol* 2004; 137:77.
68. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. *Arch Ophthalmol* 1991; 109:1673(<https://jamanetwork.com/journals/jamaophthalmology/article-abstract/639424> adresinden ulaşılmıştır).
69. Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study. *Brain* 2001; 124:468.
70. Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. *J Neurol* 2004; 251:996.
71. Rocca MA, Hickman SJ, Bö L, et al. Imaging the optic nerve in multiple sclerosis. *Mult Scler* 2005; 11:537.
72. Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. *J Neurol Neurosurg Psychiatry* 2003; 74:1577.
73. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. *Ann Neurol* 1997; 41:392.
74. Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. *J Neurol* 2005; 252:396.
75. Fraser CL, Klistorner A, Graham SL, et al. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. *Ophthalmology* 2006; 113:323.e1.
76. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. *Ann Neurol* 2005; 58:383.
77. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. *Neurology* 2009; 73:46.

78. Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. *J Neurol Neurosurg Psychiatry* 2009; 80:1002.
79. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. *J Neurol Neurosurg Psychiatry* 2010; 81:109.
80. Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor  $\alpha 1$  subunit in patients with isolated optic neuritis. *JAMA Neurol* 2015; 72:187.
81. Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. *Neurol Neuroimmunol Neuroinflamm* 2015; 2:e131.
82. Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. *J Neuroinflammation* 2016; 13:282.
83. Dos Passos GR, Oliveira LM, da Costa BK, et al. MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. *Front Neurol* 2018; 9:217.
84. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. *Arch Ophthalmol* 1997; 115:1545.
85. Kupersmith MJ, Gal RL, Beck RW, et al. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. *Neurology* 2007; 69:508.
86. Hickman SJ, Toosy AT, Miskiel KA, et al. Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. *J Neurol* 2004; 251:996.
87. Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. *Arch Neurol* 2012; 69:65.
88. Absoud M, Cummins C, Desai N, et al. Childhood optic neuritis clinical features and outcome. *Arch Dis Child* 2011; 96:860.
89. Deschamps R, Gueguen A, Lecler A, et al. Acute idiopathic optic neuritis: not always benign. *Eur J Neurol* 2018; 25:1378.
90. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. *Arch Ophthalmol* 2003; 121:944.
91. Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. *J Neurol* 2005; 252:396.
92. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. *Neurology* 2009; 72:542.
93. Alper G, Wang L. Demyelinating optic neuritis in children. *J Child Neurol* 2009; 24:45.
94. Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. *Arch Neurol* 2004; 61:1401.
95. Kheradvar A, Tabassi AR, Nikbin B, et al. Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study. *Mult Scler* 2004; 10:526.
96. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. *N Engl J Med* 2003; 349:139.
97. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. *Mult Scler* 2005; 11:492.
98. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000; 54:2039.
99. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. *N Engl J Med* 1992; 326:581.

100. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. *Eur J Neurol* 2008; 15:1163.
101. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. *Neurology* 2004; 63:1081.
102. Horton L, Conger A, Conger D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. *Neurology* 2013; 80:1862.
103. Sühs KW, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. *Ann Neurol* 2012; 72:199.
104. Toosy AT, Mason DF, Miller DH. Optic neuritis. *Lancet Neurol* 2014; 13:83.